Abstract
Trans-arterial radioembolization (TARE) is an established treatment for inoperable hepatocellular carcinoma and liver metastases from Carcinoma of gastrointestinal tract. Radiation-induced toxicity to the lung parenchyma is the dose-limiting factor in TARE. Pretreatment hepatopulmonary shunt (HPS) is estimated by gamma camera method by transarterial administration of 370MBq 99mTc macro aggregated albumin. We have developed HPS software on XELERIS-1.123 workstation, GE medical systems, Milwaukee, USA, for accurate calculation of HPS. This software has also been tested on a higher version of XELERIS workstation, and it has been found to work well in all versions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
